Myasthenia gravis (MG) is a rare neuromuscular disorder characterized by muscle weakness and fatigue. Clinical management of MG has historically focused on symptomatic treatment with the acetylcholinesterase inhibitor pyridostigmine followed by chronic immunosuppressive therapies (e.g., glucocorticoids). However, the MG pipeline is beginning to bring novel therapies with unique MOAs to the market, highlighted by the 2017 FDA approval of eculizumab (Soliris). As the MG current treatment landscape continues to evolve, this report offers insights from real-world claims data into prescribing trends in MG to help new players better understand current treatment practices in MG and help define the market niche for their emerging products.
Markets covered: United States.
Real-world data: Longitudinal patient-level claims data analysis.
Key companies: Alexion Pharmaceuticals, Roche, Sanofi, Catalyst Pharmaceuticals, GSK
Key drugs covered: pyridostigmine, prednisone, azathioprine, mycophenolate mofetil, tacrolimus, cyclosporine, Rituxan, methotrexate, Soliris, belimumab, intravenous immunoglobulins .
Key analysis provided:
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.